Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission: ⭐️🔼Baseline physician global VAS 🔼flare in 16 weeks after tapering to 2/3 of standard dose. ⭐️🔼Age 🔼flare within 16 weeks after tapering to 1/2 dose Abst #0929 #ACR21 @RheumNow https://t.co/EFiwKA8z99

#ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts ⭐️TNFi use ⬆️ disease activity vs ABA in obese pts ⭐️TNFi use ⬆️ activity vs TCZ in non-obese pts ⭐️No diff w RTX, Tofa ▶️Further research needed: Wt-based dosing? SC vs IV? https://t.co/K8WycPTgxW @Rheumnow #ACRBest

• https://bit.ly/3H1GMDI

Let's look at MI first. Well, the numbers don't look great for tofa here. fatal MI very small numbers non-fatal MI - well that doesn't look good (do we have combined both tofa doses vs TNFi?) HR > 2 seems less than ideal - this would represent a substantial RF #ACR21 @RheumNow https://t.co/5HSXFrMJCu

Do you order EKGs in everyone starting HCQ? Do you avoid HCQ in patients with heart failure? Will these abstracts impact your practice? Click on link to read more....#ACR21 @rheumnow #HCQ https://t.co/fvUZAvNWa8

• Dr. John Cush on Twitter: "Prolonging the Controversy of Hydroxychloroquin…

Dr Naovarat reports on 18 year outcomes of HIV and rheumatic disease. 16 patients treated with TNFi, including 2 who switched to tocilizumab and ustekinumab. No major infections. Rising viral load in 1 led to discontinue. Abstr#0965 #ACR21 @RheumNow https://t.co/jcGPaURKmb

Physician global score only predictor of axSpA flares when tapering TNFi ⭐️Changes in imaging did not predict flare Abs#929 #ACR21 @RheumNow https://t.co/vVn6ARKJu0 https://t.co/FlVtlLmTfl

• Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare …

For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx

#ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX: ▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX. ⭐️Age, sex, waist circumference, BMI are risks @Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7

• https://bit.ly/3bLe4Jb